Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Dr. Roger Dansey Dr. Roger Dansey joins Ottimo Pharma Limited Board of Directors Dansey, a former senior executive at Pfizer ...

Seeing that, PFE's management tries to position the firm as best as it can. First, after Pfizer acquired Seagen in 2023, its debt load increased, but this way the consolidated firm has become a ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren’t in bad shape either. So, is it the right time to bet on ...

PFE’s New Drugs & Seagen Acquisition to Drive Growth Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven by its key in-line products like ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Fortunately, Pfizer has been preparing for this. The company used a chunk of its pandemic-related profits to acquire Seagen for $43 billion -- the acquisition positions Pfizer to grow its oncology ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...